What You Should Know:
– Lunit, a provider of AI solutions for cancer diagnostics and therapeutics, has announced a strategic collaboration with AstraZeneca, a global pharmaceutical company, to develop AI-powered digital pathology solutions.
– The partnership aims to improve cancer treatment by leveraging AI to analyze tissue samples and predict the likelihood of specific genetic mutations.
Focusing on Lung Cancer Treatment with AI
The collaboration will initially focus on developing Lunit SCOPE Genotype Predictor, an AI-powered tool that analyzes images of stained tissue samples to predict the likelihood of non-small cell lung cancer (NSCLC) driver mutations, such as those in the Epidermal Growth Factor Receptor (EGFR) gene.
Identifying these mutations is critical for determining the most effective treatment strategies for NSCLC patients. However, traditional genomic testing can be time-consuming and resource-intensive. Lunit SCOPE Genotype Predictor offers a faster and more cost-effective approach by:
- Analyzing H&E Slides: Predicts the likelihood of EGFR and other NSCLC driver mutations directly from standard H&E-stained tissue slides.
- Prioritizing Molecular Testing: Helps prioritize patients for molecular testing based on the AI’s prediction, potentially speeding up the diagnosis and treatment process.
- Informing Treatment Decisions: Provides valuable insights to guide treatment decisions and personalize cancer care.
Empowering Healthcare Practitioners
By providing healthcare practitioners with cutting-edge AI tools, Lunit and AstraZeneca are empowering them to:
- Optimize diagnostic workflows: Streamline the process of identifying patients with specific genetic mutations.
- Prioritize molecular testing: Ensure that patients receive timely and appropriate testing.
- Personalize cancer treatment: Select the most effective therapies based on individual genetic profiles.
“We are excited to partner with AstraZeneca, a leader in oncology therapeutics, to develop and evaluate this groundbreaking technology,” said Brandon Suh, CEO of Lunit. “The integration of Lunit SCOPE Genotype Predictor as a screening test into pathology workflows promises to improve the opportunity for patients to benefit from appropriate targeted therapy, ultimately improving patient outcomes and streamlining the treatment planning process.”